Table 1.

Baseline characteristics and Chromatest results of the hypothyroid and euthyroid control groups

Parameter	Baseline hypothyroid group (n = 38)	Prospective hypothyroid group (n = 24) before treatment	Prospective hypothyroid group (n = 24) after treatment	Euthyroid control group (n = 20)	p value
Age, yearsa	40.53±13.33	38.92±13.41	38.92±13.41	35.10±7.71	0.06b, 0.25c
Females/males	31/7	19/5	19/5	16/4	1.0b, c
Free T3a (0.02–0.05 pmol/l)	0.04 (0.004–0.05)	0.04 (0.02–0.05)	0.05 (0.04–0.06)	0.05 (0.04–0.06)	0.002b, <0.001c, 0.29d
Free T4a (7.9–14.4 pmol/l)	6.17 (0.90–7.72)	6.30 (0.90–7.72)	11.32 (7.97–16.08)	10.42 (8.11–12.36)	<0.001b, c, 0.11d
TSHa (0.34–5.6 mU/l)	25.63 (6.70–100)	26.24 (6.70–100)	1.38 (0.53–5.53)	1.39 (0.61–3.59)	<0.001b, c, 0.24d
Anti-TPO positivity, %	81.60	87.50
Anti-Tg positivity, %	68.40	70.80
Tritan CCT (blue-yellow), %a	5.45 (2.80–23.40)	5.60 (2.80–10.80)	4.80 (2.60–10.50)	4.05 (2.60–6.30)	<0.001bcd, 0.002e
Protan CCT (red-green), %a	2.00 (1.00–4.90)	2.00 (1.00–3.90)	1.70 (1.00–3.40)	1.60 (0.90–2.70)	<0.001b, c, e, 0.07d

Anti-TPO = Anti-thyroperoxidase; anti-Tg = anti-thyroglobulin.

^aMedian (range).

^bBaseline hypothyroid group vs. control group.

^cProspective hypothyroid group before treatment vs. control group.

^dProspective hypothyroid group after treatment vs. control group.

^eProspective hypothyroid group before treatment vs. prospective hypothyroid group after treatment.